Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reaffirmed by equities research analysts at N+1 Singer in a research note issued to investors on Wednesday. They presently have a GBX 1,225 ($16.61) price objective on the stock. N+1 Singer’s target price points to a potential upside of 22.87% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Numis Securities reiterated an “add” rating and issued a GBX 1,208 ($16.38) price target on shares of Clinigen Group in a research note on Wednesday. Peel Hunt reiterated a “buy” rating and issued a GBX 1,350 ($18.31) price target on shares of Clinigen Group in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,360 ($18.44) price target on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank began coverage on shares of Clinigen Group in a research note on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.27) price target on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Clinigen Group presently has a consensus rating of “Buy” and a consensus target price of GBX 1,218.83 ($16.53).

Clinigen Group (CLIN) opened at GBX 997 ($13.52) on Wednesday. The company has a market cap of $1,220.00 and a P/E ratio of 33,233.33. Clinigen Group has a one year low of GBX 751.50 ($10.19) and a one year high of GBX 1,187 ($16.10).

In other Clinigen Group news, insider Chris Rigg sold 4,955 shares of the firm’s stock in a transaction on Thursday, November 23rd. The stock was sold at an average price of GBX 1,017 ($13.79), for a total value of £50,392.35 ($68,337.88).

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/17/clinigen-groups-clin-buy-rating-reaffirmed-at-n1-singer.html.

Clinigen Group Company Profile

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.